It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade
Journal
Journal of the Formosan Medical Association
Journal Volume
120
Journal Issue
1
Pages
1��4��
Date Issued
2021
Author(s)
SDGs
Other Subjects
angiogenesis inhibitor; atezolizumab; bevacizumab; ibi 305; immune checkpoint inhibitor; immunological antineoplastic agent; sorafenib; unclassified drug; programmed death 1 receptor; advanced cancer; antiangiogenic therapy; cancer immunotherapy; cancer survival; chemoembolization; combination drug therapy; drug efficacy; human; liver cell carcinoma; median survival time; overall survival; patient-reported outcome; phase 1 clinical trial (topic); phase 3 clinical trial (topic); progression free survival; response evaluation criteria in solid tumors; Short Survey; standard; treatment response; immunotherapy; liver tumor; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liver Neoplasms; Programmed Cell Death 1 Receptor
Publisher
Elsevier B.V.
Type
short survey